[go: up one dir, main page]

WO1992005797A1 - Preparation antineoplasique chimioimmunologique - Google Patents

Preparation antineoplasique chimioimmunologique Download PDF

Info

Publication number
WO1992005797A1
WO1992005797A1 PCT/JP1990/001300 JP9001300W WO9205797A1 WO 1992005797 A1 WO1992005797 A1 WO 1992005797A1 JP 9001300 W JP9001300 W JP 9001300W WO 9205797 A1 WO9205797 A1 WO 9205797A1
Authority
WO
WIPO (PCT)
Prior art keywords
anticancer
immunological
activity
chemical
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1990/001300
Other languages
English (en)
Japanese (ja)
Inventor
Shingo Nagamitu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/JP1990/001300 priority Critical patent/WO1992005797A1/fr
Publication of WO1992005797A1 publication Critical patent/WO1992005797A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient

Definitions

  • the present invention is directed to an anticancer drug preparation having both a chemical anticancer effect and an immunological anticancer effect and having a low side effect and a strong antitumor effect.
  • anticancer drug preparations used in clinical medicine are roughly classified into chemical anticancer drugs and immunological anticancer drugs.
  • the former has a greater anticancer effect than the latter, but has reduced leukopenia.
  • the product name is “Roll-A-Trade-Fluid” [Laborato-Meret ⁇ Genorebe's product name]. : HC 0 — 60, Nikko Chemicals, Inc.] and So / Revitanse Schifolate [S 0 — 15, Nikko Chemicals, Inc.] Dissolved, 0.45 m tetrafluoroethylene resin membrane filter [F1 uoropor ⁇ : Nitomo Electric Industries, Ltd.] Use heat to evaporate.
  • an aqueous solution of parin 10-stream and an aqueous solution of neocarzinostatin are added, and the mixture is immediately subjected to ultrasonic treatment, and aseptically processed into WZO emulsion.
  • other anti-cancer drugs such as adriamycin can be added.
  • this anticancer agent When this anticancer agent is injected into a carcinoma, the carcinoma begins to shrink within a few days. This topical chemical effect lasts tens of days as long as the formulation is there. New carcinomas begin to rapidly disintegrate around 3 months after injection .. The injection of the drug is given only once, and this reaction occurs after the local drug has almost disappeared. Thus, the destruction of the carcinoma is an immune response. ⁇ Once a response occurs, it lasts for three years or more as long as the carcinoma is present in the patient.
  • the anticancer substance preparation also has an extremely excellent effect in reducing the side effects, which is another object.
  • the side effects of this formulation were fever and pain due to mesothelial rupture. This side effect is not due to the formulation itself. Those who do not have cancer, if the size of carcinoma is 5 mm or less, almost no such side effects are seen
  • Percutaneous transhepatic neocarcinostatin is a patient who has been treated with this anticancer drug because of severe ascites and severe liver dysfunction due to liver cancer with cirrhosis. Injection of 2 ml of 0 U in 1 containing emulsion into one of the masses. A-fetoprotein, which is a tumor marker of liver cancer, had a dose of 4460 ng and 'm1 before injection, but the carcinoma began to collapse rapidly after 12 weeks.
  • Neochemical rutinostatin a chemical anticancer substance alone, does not exert its anticancer effects for more than a few months in a single injection.
  • neocarcinostatin which is highly concentrated in the tumor after injection and remains locally in the tumor for a long period of time, exerts a strong chemical anticancer effect and causes tumor necrosis.
  • the cell membrane and other cellular components of the necrotic cancer cells are combined with the neo-power / retinostatin 'henolin emulsion, and the bound substance is Makes the patient's immune system recognize the cancer component as a foreign substance. It takes more than about 12 weeks to establish immunity, but just about 12 weeks later, strong destruction of tumor tissue begins. This reaction progresses intensely for several months to several tens of months in proportion to the tumor volume, and tumor destruction proceeds. This immune response persists three years later, as long as the carcinoma is present. Such an intense and long-lasting destruction of cancer is still unknown today.
  • This treatment is almost always effective with only one injection. Add several small doses every few days, depending on the size of the tumor and the degree of response.
  • the total amount of neocarcinostatin used is 10,000 to 20,000 units. Almost no toxic or side effects seen in bone marrow disorders and other anticancer therapies.
  • the immune response of this product is accompanied by leukocytosis. Since the present anticancer drug preparation has an immunological reaction as its main anticancer effect, there are almost no side effects such as those observed with chemical anticancer drugs.
  • this emma / resin stably dissolves other chemical anticancer drugs without impairing its effect, if neocarzinostatin cannot be expected to have a chemical action, When it is conceivable, it can be used by additionally dissolving Adriamycin or the like. In addition, since this preparation dissolves protein, it can be used in combination with immunotherapy such as inter-fluorocarbon. Originally, neocarzinostatin is an anticancer drug mainly composed of protein components.
  • this anticancer drug formulation is to mix a chemical anticancer drug with a substance that stimulates the immune system and inject it into the tumor, thereby destroying the cancer cells with the anticancer drug and debris of the cancer cells.
  • a chemical anticancer drug to phagocytose the macrophages that have migrated by the immunostimulatory substance to enhance the immune recognition of cancer.
  • Sulfate polysaccharides disulfate polysaccharides—dextran sulphate, chondroitin sulphate, heparin, etc. as substances that stimulate the immune system.
  • Various lipids and natural oils such as linoleic acid and synthetic oils are mixed as lipids such as mysin, etc.
  • neocarcinostatin, heparin, rebiodol and interface Emaruji Yo down its physical properties of the active agent was prepared by Ji mixed, the t. this Emma / register Yo down the chemical anti-cancer effect and have you in the immunological anti-cancer action most excellent characteristics were shown rats When injected into the abdominal cavity of the guinea pig, it diffuses and diffuses without dripping for a long time.
  • heparin is used as a spacer
  • neocarzinostatin, a protein anticancer drug, and lipiodol, an oily substance combine to form a large molecule. Think of it as a thing.
  • the chemical / immunological anticancer preparation of the present invention exhibits excellent effects in treating cancer, sarcoma, and the like, and has a chemical / immunological effect on other anticancer agents. It is also used as a base that imparts an anticancer effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparation antinéoplasique comprenant un mélange de néocarcinostatine (y compris ses dérivés d'héparine, d'ester iodé éthylique d'acide gras d'huile de pavot, d'eau et d'agent tenso-actif, et ayant à la fois des activités antinéoplasiques chimique et immunologique. Cette préparation fait preuve d'une activité chimique anticarcinogénique juste après l'injection et d'une activité immunologique environ 12 semaines après, et l'activité immunologique est de loin plus importante que l'activité chimique. L'activité de la préparation se poursuit pendant trois ans, aussi longtemps que les cellules cancéreuses restent intactes. Etant donné que cette préparation peut facilement dissoudre divers autres agents antinéoplasiques, elle peut transmettre à ces agents une activité antinéoplasique immunologique.
PCT/JP1990/001300 1990-10-05 1990-10-05 Preparation antineoplasique chimioimmunologique Ceased WO1992005797A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP1990/001300 WO1992005797A1 (fr) 1990-10-05 1990-10-05 Preparation antineoplasique chimioimmunologique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1990/001300 WO1992005797A1 (fr) 1990-10-05 1990-10-05 Preparation antineoplasique chimioimmunologique

Publications (1)

Publication Number Publication Date
WO1992005797A1 true WO1992005797A1 (fr) 1992-04-16

Family

ID=13986766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1990/001300 Ceased WO1992005797A1 (fr) 1990-10-05 1990-10-05 Preparation antineoplasique chimioimmunologique

Country Status (1)

Country Link
WO (1) WO1992005797A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585058A1 (fr) * 1992-08-25 1994-03-02 Scotia Holdings Plc Compositions pharmaceutiques contenant des acides gras et de l'héparine
US5954737A (en) * 1997-12-19 1999-09-21 Neurovasx, Inc. Thrombus macerator catheter
CN107287029A (zh) * 2016-05-30 2017-10-24 江苏恒瑞医药股份有限公司 一种碘化植物油脂肪酸乙酯的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4888220A (fr) * 1972-03-04 1973-11-19
JPS52139789A (en) * 1976-05-14 1977-11-21 Microbial Chem Res Found Method of preparing stable powder of neocarzinostatin
JPS6485922A (en) * 1986-09-19 1989-03-30 Yamanouchi Pharma Co Ltd Neocarzinostatin derivative composition for noninjection administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4888220A (fr) * 1972-03-04 1973-11-19
JPS52139789A (en) * 1976-05-14 1977-11-21 Microbial Chem Res Found Method of preparing stable powder of neocarzinostatin
JPS6485922A (en) * 1986-09-19 1989-03-30 Yamanouchi Pharma Co Ltd Neocarzinostatin derivative composition for noninjection administration

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0585058A1 (fr) * 1992-08-25 1994-03-02 Scotia Holdings Plc Compositions pharmaceutiques contenant des acides gras et de l'héparine
US5954737A (en) * 1997-12-19 1999-09-21 Neurovasx, Inc. Thrombus macerator catheter
CN107287029A (zh) * 2016-05-30 2017-10-24 江苏恒瑞医药股份有限公司 一种碘化植物油脂肪酸乙酯的制备方法
CN107287029B (zh) * 2016-05-30 2021-04-06 江苏恒瑞医药股份有限公司 一种碘化植物油脂肪酸乙酯的制备方法

Similar Documents

Publication Publication Date Title
Takahashi et al. Attempt at local administration of anticancer agents in the form of fat emulsion
JP2023158064A (ja) 生薬等含有医薬組成物（拾）
JPH01146829A (ja) 超音波による腫瘍治療用生理作用増強剤
KR880008800A (ko) 난용성 활성성분을 위한 치료계
NZ501950A (en) Medicinal compositions for application to mucosa
KR20080091747A (ko) 알부민 안정화된 파클리탁셀을 포함하는 고형성 종양 치료용 약물 제형
WO2003049694A3 (fr) Methodes therapeutiques de traitement d'un lymphome non hodgkinien
JPS61151123A (ja) 安定化された３―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤
TW201242606A (en) Hemostatic preparation containing an extract of golden moss
WO1992005797A1 (fr) Preparation antineoplasique chimioimmunologique
RU2593848C2 (ru) Противоопухолевое средство, содержащее диоксид углерода в качестве активного ингредиента
US3548052A (en) Heparin compositions and methods of using same
WO2014176417A1 (fr) Préparation topique pour contourner un tractus gastro-intestinal, administration d'agents thérapeutiques et système d'administration de médicament trans-épithéliale
Weyrauch et al. Dissemination of bladder neoplasms by endoscopic electroresection
JPH0543687B2 (fr)
CN108685944A (zh) 包含活体染料的药物组合物及其应用
CN104703626B (zh) 用于治疗癌症的基于碘油的抗肿瘤乳剂
JPWO1992005797A1 (ja) 化学・免疫学的抗癌物質製剤
Carr et al. Lymphatic metastasis; lymphangiochemotherapy of mammary cancer: ascitic form of rat mammary adenocarcinoma 13762
JPS5839619A (ja) 医薬組成物及びその製造方法
Javadpour et al. Bladder toxicity due to cyclophosphamide: Experimental induction and treatment
EA200100223A3 (ru) Воднодисперсная лекарственная форма ивермектина для лечения экто- и эндопаразитозов
Selye Effect of inflammation upon the growth of transplantable neoplasms as demonstrated by the “double granuloma-pouch” technique
JPS6053150A (ja) ゴム系粘着性膏体
CN108686218A (zh) 包含化学消融剂和疫苗佐剂的药物组合物及其用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BG BR CA FI HU JP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA